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Multiparametric magnetic resonance imaging in mucosal primary head and neck
cancer: A prospective imaging biomarker study
Abstract
Background: Radical radiotherapy, with or without concomitant chemotherapy forms the mainstay of
organ preservation approaches in mucosal primary head and neck cancer. Despite technical advances in
cancer imaging and radiotherapy administration, a significant proportion of patients fail to achieve a
complete response to treatment. For those patients who do achieve a complete response, acute and late
toxicities remain a cause of morbidity. A critical need therefore exists for imaging biomarkers which are
capable of informing patient selection for both treatment intensification and de-escalation strategies.
Methods/design: A prospective imaging study has been initiated, aiming to recruit patients undergoing
radical radiotherapy (RT) or chemoradiotherapy (CRT) for mucosal primary head and neck cancer
(MPHNC). Eligible patients are imaged using FDG-PET/CT before treatment, at the end of week 3 of
treatment and 12 weeks after treatment completion according to local imaging policy. Functional MRI
using diffusion weighted (DWI), blood oxygen level-dependent (BOLD ) and dynamic contrast enhanced
(DCE) sequences is carried out prior to, during and following treatment. Information regarding treatment
outcomes will be collected, as well as physician-scored and patient-reported toxicity. Discussion: The
primary objective is to determine the correlation of functional MRI sequences with tumour response as
determined by FDG-PET/CT and clinical findings at 12 weeks post-treatment and with local control at 12
months post-treatment. Secondary objectives include prospective correlation of functional MRI and PET
imaging with disease-free survival and overall survival, defining the optimal time points for functional MRI
assessment of treatment response, and determining the sensitivity and specificity of functional MRI
sequences for assessment of potential residual disease following treatment. If the study is able to
successfully characterise tumours based on their functional MRI scan characteristics, this would pave the
way for further studies refining treatment approaches based on prognostic and predictive imaging data.
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Multiparametric magnetic resonance
imaging in mucosal primary head and neck
cancer: a prospective imaging biomarker
study
Christopher N Rumley1,2,3*, Mark T Lee1,2, Lois Holloway1,2,3,5,6, Robba Rai1,2, Myo Min7, Dion Forstner1,2,3,4,
Allan Fowler1 and Gary Liney1,2,3,5

Abstract
Background: Radical radiotherapy, with or without concomitant chemotherapy forms the mainstay of organ
preservation approaches in mucosal primary head and neck cancer. Despite technical advances in cancer imaging and
radiotherapy administration, a significant proportion of patients fail to achieve a complete response to treatment. For
those patients who do achieve a complete response, acute and late toxicities remain a cause of morbidity. A critical
need therefore exists for imaging biomarkers which are capable of informing patient selection for both treatment
intensification and de-escalation strategies.
Methods/design: A prospective imaging study has been initiated, aiming to recruit patients undergoing radical
radiotherapy (RT) or chemoradiotherapy (CRT) for mucosal primary head and neck cancer (MPHNC). Eligible patients
are imaged using FDG-PET/CT before treatment, at the end of week 3 of treatment and 12 weeks after treatment
completion according to local imaging policy. Functional MRI using diffusion weighted (DWI), blood oxygen leveldependent (BOLD) and dynamic contrast enhanced (DCE) sequences is carried out prior to, during and following
treatment. Information regarding treatment outcomes will be collected, as well as physician-scored and patientreported toxicity.
Discussion: The primary objective is to determine the correlation of functional MRI sequences with tumour response
as determined by FDG-PET/CT and clinical findings at 12 weeks post-treatment and with local control at 12 months
post-treatment. Secondary objectives include prospective correlation of functional MRI and PET imaging with diseasefree survival and overall survival, defining the optimal time points for functional MRI assessment of treatment response,
and determining the sensitivity and specificity of functional MRI sequences for assessment of potential residual disease
following treatment. If the study is able to successfully characterise tumours based on their functional MRI scan
characteristics, this would pave the way for further studies refining treatment approaches based on prognostic and
predictive imaging data.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12616000534482 (26 April 2016).
Keywords: Head and neck cancer, MRI, Functional imaging, Hypoxia, Predictive role, Chemoradiation, Dynamic
contrast-enhanced MRI, Diffusion-weighted imaging
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Background
Mucosal primary head and neck cancer (MPHNC) has
an estimated incidence of over 900,000 cases per year,
and is associated with significant mortality, causing more
than 350,000 deaths per year[1]. Organ preservation
strategies involve the administration of a radical dose of
radiation therapy, usually with concomitant chemotherapy, producing 5-year overall survival rates of between
30 and 50% [2]. Despite technical improvements in
radiotherapy, significant toxicity may result from these
treatments [3, 4].
Prognostication and treatment strategies are informed by clinical features [5] and increasingly by
tumour biological features, notably preceding infection with oncogenic strains of human papilloma virus
(HPV) [6, 7]. Reliable imaging biomarkers may therefore provide useful data to facilitate adaptive approaches including treatment intensification for poor
responders and de-intensification for good responders
[8]. Such strategies may improve the therapeutic ratio
by reducing dose to organs at risk and increasing
dose to areas harbouring subvolumes of more resistant tumour.
Positron-emission tomography using 18F–fluorodeoxyglucose (FDG-PET) is currently a standard investigation
for initial staging of MPHNC. Retrospective studies have
described FDG-PET’s performance in assessing disease
following radical radiotherapy [9, 10] and its value in
decision-making around surgical salvage has been demonstrated in a prospective trial [11]. Some limitations remain
however, with the possibility of false-positive results due
to benign tissue inflammation and of false-negative results
due to limited spatial resolution.
Magnetic resonance imaging (MRI) has an established
role in diagnosis and staging of MPHNC, and its use in
radiotherapy planning continues to expand [12]. MRI has
superior spatial resolution, better soft tissue definition and
does not employ ionising radiation. Furthermore, functional sequences can provide additional information on
tissue composition and biology which is not revealed by
standard anatomical T1 and T2 weighted scans.
Diffusion-weighted imaging (DWI) characterises tissue based on movement of water within a volume.
The diffusivity of water molecules depends on microstructural features of the tissue, such as cellular size
and density, and may be quantified with the apparent
diffusion coefficient (ADC). Its applications in the
upper aerodigestive tract were previously limited by
technical factors such as susceptibility artefact from
air-tissue interfaces and low signal-to-noise ratio.
Modern scanning techniques have been able to overcome many of these issues, and DWI measurements
before, during and following RT have been investigated as a diagnostic and prognostic tool [13–18].
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Dynamic contrast-enhanced (DCE) MRI provides information on abnormal tumour vasculature, by assessing
the travel of gadolinium contrast agent between intravascular and extracellular extravascular space (EES) by
means of sequential T1-weighted scans with high temporal resolution. With knowledge of the pre-contrast T1
tissue values, and the concentration-time course of contrast in feeding blood vessels, pharmacokinetic modelling can generate quantitative parameters for analysis of
tumour perfusion [19]. These include Ktrans (the volume
transfer constant between blood plasma and EES), Kep
(the rate constant between EES and blood plasma) and
Ve (the fractional volume of EES). The values of these
parameters, as well as their distribution in the volume
imaged, have been investigated as potential imaging biomarkers both before and after treatment for MPHNC
[20–30].
Blood oxygen level–dependent (BOLD) MRI utilises
local changes in magnetic susceptibility due to the presence of paramagnetic deoxyhaemoglobin. An increase in
deoxyhaemoglobin shortens transverse relaxation time
T2*, giving a qualitative indication of tissue hypoxia [31].
The rate of transverse relaxation R2* (1/T2*) can be
measured with a multiple-echo gradient echo sequence
and has been shown to correlate with tissue hypoxia as
measured by polarographic electrodes and immunohistochemistry [32–34]. Pre-clinical and early clinical results suggest that R2* may be a useful biomarker for
radiation response and for treatment outcomes [35–37].
Our group completed a pilot study of functional MRI
and FDG-PET in a cohort of patients undergoing radical
radiotherapy for MPHNC, indicating that carrying out
sequential DWI and R2* studies before, during and after
radiotherapy was feasible. Initial results, including correlations between imaging studies have been published,
while mature data regarding clinical outcomes are
awaited [18]. Following this we have initiated a prospective observational study named “MRI in MPHNC”, which
aims to gather data on the utility of functional imaging sequences with DWI, DCE and BOLD MRI as biomarkers
for prediction and assessment of treatment response.

Methods
Study design and consent

This study is a prospective single arm observational trial
of patients undergoing curative intent primary radiotherapy, with or without chemotherapy, for MPHNC at Liverpool and Campbelltown Hospitals. Patients are identified
and evaluated by the multidisciplinary team. Informed
consent is obtained by medically trained personnel as per
the trial delegation log. Administrative support, including
travel funding for study scans, is provided by clinical trials
unit staff.

Rumley et al. BMC Cancer (2017) 17:475

Hypotheses

1. Functional MRI can be used as a reliable imaging
biomarker in prediction of treatment response
(radiotherapy ± chemotherapy) in MPHNC
2. Functional MRI can be used as an alternative
functional imaging study to FDG-PET scan in assessing response after radiotherapy ± chemotherapy
3. Functional MRI can differentiate between recurrent
or residual malignant disease and post-treatment tissue changes following radiotherapy ± chemotherapy
Objectives
Primary objective

To determine the correlation of pre-, during treatment
and post-radiotherapy (± chemotherapy) functional MRI
with tumour response at 3 months by FDG-PET scan
and with local control at 12 months.
Secondary objectives

1. To prospectively correlate different MRI sequences
and FDG-PET findings with disease-free survival
(DFS) and overall survival (OS)
2. To determine the best time to perform MRI during
radiotherapy treatment for assessing tumour
response and local control
3. To determine the sensitivity and specificity of
functional MRI sequences compared with FDG-PET
in assessment of potential residual and recurrent
MPHNC following definitive radiotherapy
4. To assess consistency of image registration, signal
information and associated analyses over a relevant
time frame in a representative subset of patients
Endpoints
Primary endpoints

Correlation of functional MRI sequences with PET-CT
at 3 months following treatment and local control at
12 months, including:
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Secondary endpoints

Correlation of different MRI measurements with 1 and
2 year DFS and OS including:
 Determination of the ability of DWI for detecting

residual or recurrent cancer
 Assessment of functional MRI in correlation with

FDG-PET metabolic response at 3 months and local
control at 12 months
Subject selection
Inclusion criteria
 18 years or older
 Have the ability to give informed consent
 Histologically-proven invasive mucosal primary

squamous cell carcinoma of head and neck region or
patients with tumours strongly suspicious for
mucosal primary head and neck cancer due to
clinical features AND fine needle aspiration (FNA)
cytology assessment
 Primary mucosal head and neck cancer (≥T2 and/or
≥N1) AND no evidence of metastatic disease on
staging PET/CT or CT (chest ± abdomen ± pelvis)
 Patient undergoing curative intent primary
radiotherapy ± chemotherapy
Exclusion criteria
 Contraindication to MRI studies
 Significant claustrophobia
 Pacemaker/implantable defibrillator
 Implanted metals e.g. Intraocular clips
 Known allergic reaction to gadolinium (Gd)-

DTPA
 Previous radiotherapy to the area to be treated
 Primary cancer surgery to the affected area
 Other malignancy within 5 years of the current

diagnosis, with the exception of successfully treated
basal cell or squamous cell skin carcinoma, in situ
melanoma, or carcinoma in situ of the cervix

 Measurement of restricted water diffusion as on

Early withdrawal of subjects

DWI, which can be a marker of high cellularity
within a tumour, using ADC values, ΔADC and
parameter maps of ADC.
 Measurement of tumour perfusion characteristics
from DCE-MRI, using parameter maps and calculated values based on inflow and outflow (Ktrans, Kep)
as well as degree of contrast enhancement of tissues
(Relative Signal Intensity, RSI).
 Tumour size as defined on anatomical imaging using
T2-weighted and/or T1-weighted Volume Interpolated Breathhold Examination (VIBE) Dixon MRI.

If a patient expresses wishes to withdraw from the trial,
site staff will explain the importance of maintaining
follow-up. A patient may withdraw, or be withdrawn,
from the trial for the following reasons:
 Unacceptable toxicity
 Requests or requires early discontinuation for any

reason
 Intercurrent illness which prevents further

treatment/follow-up
 Withdrawal of consent for treatment by patient
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 Develops, during the course of the study, symptoms

or conditions listed in the exclusion criteria
 Investigator discretion
The investigator will also withdraw all subjects from
the study if the study is terminated. Subjects are free to
withdraw from the study at any time upon their request
or the request of their legally acceptable representative.
Patients may re-consent if they change their mind following withdrawal, to resume participation on this trial.
The patient will however remain in the trial for the purposes of follow-up and data analysis unless they specifically request otherwise.
Radiotherapy

All participants will receive standard treatment according to locally agreed protocols [38], based on international evidence-based practice guidelines. This study
does not involve a treatment intervention or additional
ionising radiation exposure. Therefore, there will not be
any additional radiation dose or related side effects by
participating in this trial. All imaging performed with
ionising radiation is part of standard clinical practice.
Chemotherapy

All participants will be treated according to locally agreed
protocols [38], based on international evidence-based
practice guidelines. Therefore, there will not be any additional chemotherapy related side effects by participating
in this trial.
Imaging
Imaging schedule

Functional MRI studies are carried out prior to commencing treatment, then weeks 2, 3, 5 and 6 during
treatment, followed by 1 month and 3 months posttreatment (Fig. 1).
Imaging procedures

All patients scanned on a 3 T wide bore scanner (Skyra,
Siemens, Erlangen, Germany) using a 20-channel head
and neck coil (Fig. 2). Morphological and functional sequences are obtained in the same scan session.
Morphological MRI
Sagittal T2 TIRM (turbo inversion recovery magnitude).
Axial T2 TSE DIXON water-only.
Coronal T2 TSE DIXON water-only.
Axial T1 DIXON water-only, pre- and post-contrast.
Functional MRI
Coronal BOLD
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 5 mm slice thickness, 2 averages, 8 slices through

region of interest
 In-plane resolution 1.7 × 1.7 mm
 TR 500 ms, TE 2.46 to 56.58 ms (12 echoes, 4.92 ms

spacing)
Axial DWI
 Readout segmentation of long variable echo-trains

(RESOLVE) sequence
3 mm slice thickness
In-plane resolution 0.4 × 0.4 mm
3-scan trace, monopolar
b = 50 s/mm2 with one average, b = 800 s/mm2
with 3 averages, calculated image at b = 1400 s/mm2
 Bandwidth 868 Hz/Px





Repeat coronal BOLD
 Gradient echo imaging with multiple echoes
 5 mm slice thickness, 2 averages, 8 slices through

region of interest
 In-plane resolution 1.7 × 1.7 mm
 TR 500 ms, TE 2.46 to 56.58 ms (12 echoes, 4.92 ms

spacing)
DCE scans
 2 x 3D coronal T1 VIBE (volumetric interpolated

breath-hold examination) scans for T1-mapping
 2° and 15° flip angles
 3 mm slice thickness
 In-plane resolution 1 × 1 mm
 Acquisition time 1 m 21 s
 Bandwidth 440 Hz/Px
 TWIST (Time-resolved angiography With
Interleaved Stochastic Trajectories)
 Slice thickness 3 mm
 In-plane resolution 1 × 1 mm
 TR 3.06 ms, TE 1.35 ms
 Bandwidth 800 Hz/Px
 i.v. gadobutrol (Gadovist, Bayer) 0.1 mL/kg,
capped at a maximum of 7.5 mL; injection of
contrast immediately before 4th measurement,
4 ml/s with 20 ml saline flush
 Scan for total 60 timepoints, temporal resolution
5.64 s
 Data acquired for 5 m 33 s
Hop on hop off sub-study scans (week −3 to 0 only)
 Patients who consent to the sub-study get up from

the couch and are repositioned a few minutes later
 Gradient echo imaging with multiple echoes

 Axial T1, T2 and DWI scans are repeated

Rumley et al. BMC Cancer (2017) 17:475
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Fig. 1 Treatment, imaging and clinical assessment schedule for MRI in MPHNC study

Statistical plan
Sample size determination

Based on our previous study using week 3 FDG-PET scan
in head and neck cancer patients, the following sample
size calculation is made. To test a significant FDG-PET
complete metabolic response (CMR) rate of 87% in the
MRI-positive group versus an FDG-PET CMR rate of 51%
in the MRI-negative group, the study will need to recruit
55 patients in total to reach 80% power (at 5% significance
level). This number is based on an assumption that the
MRI-positive group and MRI-negative group will be balanced (e.g. 50%:50% but is powered to allow up to a
40%:60% biased ratio). It is anticipated that recruitment
will be completed in 24 months. Patients will be offered
participation in the “hop on hop off” sub-study, with a recruitment goal of 20.

DWI
High ADC values will be considered a good response
(positive MRI) and low ADC values a poor response
(negative MRI).
DCE MRI
A reduction in blood inflow and outflow (e.g. Ktrans and
Kep) will be considered a good response (positive MRI)
and either no change or an increase will be considered a
poor response (negative MRI).
BOLD
A reduction in R2* values will be considered a good response
(positive MRI) and either no change or increase in R2* values
will be considered a poor response (negative MRI).
Definition of local control

Assessment of MRI sequences

MRI scans will be determined as a good response
(e.g. positive) or poor response (e.g. negative) based on
the following definitions for endpoint analysis:

FDG-PET response at 12 weeks will be defined as a
complete metabolic response, partial metabolic response,
stable metabolic disease or progressive metabolic disease
based on visual assessment by the nuclear medicine

Rumley et al. BMC Cancer (2017) 17:475
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Fig. 2 Research scan patient setup for MRI in MPHNC study

physician’s report. Local control for patients will be assessed
at 12 months as indicated by having no evidence of local
disease on clinical (including endoscopic) examinations and
imaging studies at 12 months. Tumour response will be
assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1[39] which is the internationally recognised gold standard assessment method on
the evaluation of therapeutic response in solid tumours.

Statistical analysis

Statistical analyses will be performed by using software
SPSS and p < 0.05 will be considered statistically significant.
Chi-square test will be used to compare the prevalence of
FDG-PET CMR between MRI-positive and negative
groups. Comparisons of the ADC values/maps of pre-,
intra- and post-treatment DWI images will be performed
by using one way analysis of variance (ANOVA) test. Comparisons of the DCE parameters such as Ktrans, Kep, area
under the curve (AUC) at initial 60 and 90 s of pre-, intraand post-treatment will be performed by using the KruskalWallis test. To determine the sensitivity and specificity of
DWI and DCE parameters for FDG-PET CMR and
12 month local control, Kappa association statistics will be
used. Receiver operator characteristics (ROC) will be used
to obtain an optimal threshold for individual MRI
parameters.

Data collection

General baseline demographic data will be collected.
Other data collection can be defined by the 6 general
categories below:

Quality of life
 Baseline
 Final week of chemoradiotherapy
 Follow up visits 1, 3, 6, 12, 18, 24, 30 and 36 months

post treatment
 Assessed using University of Washington Quality of

Life Questionnaire (UW-QOL v4)[40]
Blood tests





Baseline
Weeks 2, 3, 5, 6
Follow up visits 1 and 3 months post-treatment
Consist of full blood count and basic biochemistry
panel including urea, creatinine, sodium, potassium
and chloride

Toxicity
 Acute toxicities – dry mouth, dysphagia, pain,

weight loss, oral mucositis, radiation dermatitis,
dygeusia,
 Baseline, weekly during treatment
 Follow up visits 1 and 3 months post treatments
 Late toxicities – dry mouth, skin induration,
osteonecrosis of jaw, voice alteration, oral mucositis,
dysphagia, hearing, tracheostomy, laryngectomy,
tube feeding
 At follow up visits 3, 6, 12, 18, 24, 30 and
36 months post treatment
 Using CTCAE version 4.0
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 Serious adverse events to be reported to the HREC

for review
Swallowing assessment
 Baseline
 Final week of chemoradiotherapy
 Follow up visits 1, 3, 6, 12, 18, 24, 30 and 36 months

post treatment
Scans
 Functional MRI scans as per Fig. 1 and Imaging

procedures above
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the Radiation Oncology research office located at the
Ingham Institute, Liverpool Hospital, either on a password protected computer or in files kept in a locked
room. Access to this information will be limited to the
principal investigator, research assistants and statistician
as authorized by the delegation log.
Timelines/milestones

The study started recruitment after ethics approval was
granted. A sample size of 55 has been selected for this
study for the reasons discussed above. Initial projections
suggested this could be achieved within 24 months,
however this timeframe will be reviewed as recruitment
progresses.

 As per standard of care, a PET/CT will be carried

out at week 3 of chemoradiotherapy treatment and
then at 3 months following completion of
chemoradiotherapy treatment
Treatment data
 The dose and duration of treatment will be

recorded.
Data handling and record keeping

All imaging datasets will be de-identified and stored in a
secure research drive at the Cancer Therapy Centre, Liverpool Hospital after recruiting patients to the study. Contours will be performed by radiation oncologists/fellows
and saved on the research drive. Datasets will be imported
into MATLAB (MathWorks Inc. Massachusetts, United
States) and similar mathematical analysis programs for
data-analysis. Data analysis will be in line with study aims.
The investigator site file and patient study file will be
kept at the Ingham Institute Liverpool and will be accessible only by clinical trials staff.
Confidentiality

Subject confidentiality is strictly held in trust by the participating investigators, research staff, the sponsoring institution and their agents. The study documentation,
data and all other information generated will be held in
strict confidence. No information concerning the study
or the data will be released to any unauthorized third
party, without prior written approval of the HREC and
the principal investigator. Clinical information will not
be released without written permission of the subject,
except as necessary for monitoring by Human Research
Ethics Committee (HREC) or regulatory agencies.

Publication and dissemination

The results of the study will be submitted for publication
in peer-reviewed journals and for presentation at scientific meetings. Participants in the study will be notified
of study results in writing.

Discussion
In recent years intensity-modulated RT, along with advanced diagnostic and on-treatment imaging technologies, have improved the therapeutic ratio in head and
neck cancer [41]. The enhanced ability to dose-paint and
the recognition of heterogeneity within tumours gives
rise to the promise of functional image-guided RT
(fIGRT), where subvolumes may be treated to differing
doses according to imaging-derived parameters. Longitudinal diffusion-weighted imaging has already been
shown to be feasible in MRI-guided cobalt radiotherapy
systems [42], suggesting that the addition of functional
as well as anatomical imaging may serve to improve outcomes with these systems, as well as in the MRI-guided
linear accelerators in development.
Our protocol builds on our earlier work which established the feasibility of serial functional MRI during a
course of treatment for MPHNC. Refinements to the imaging protocol include the addition of DCE sequences,
which may be expected to add further value [43], and
the expansion of the BOLD sequence to acquire multiple
slices across a volume, an imaging technique which may
be more reliable than BOLD imaging carried out on single slices [44]. The additional information gained from
the enhanced suite of imaging sequences in the current
study will help to define which sequences, at which time
points, can be used to adapt and personalise radiotherapy treatment. This information will then feed into the
design of interventional studies of adaptive RT.

Records retention

It is the investigators’ responsibility to retain study essential documents for at least 15 years after the completion of this clinical trial. All information will be stored in
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